February 2, 2018 PR-M02-18-NI-007
WUXI, China and HOUSTON, Jan. 29, 2018 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Aravive Biologics, Inc., today announced plans to expand their biologics manufacturing collaboration, based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive's lead drug candidate, AVB-S6-500 (previously referred to as Aravive-S6). The decision follows the successful filing of a U.S. Investigational New Drug application (IND) for AVB-S6-500, a novel GAS6-AXL pathway inhibitor which Aravive is developing for the treatment of cancer and non-malignant fibrotic conditions.
"We are very pleased to be part of the continuing development of AVB-S6-500 and are excited about the potential that this first-in-class molecule has shown to date as an innovative new therapy for people with cancer and fibrotic disease," said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. "We also look forward to collaborating with Aravive over the coming years on further molecules in their pipeline. Aravive's desire to continue and build upon its relationship with WuXi Biologics is a strong validation of the premier quality and global excellence of our services. We strive to make life-saving biologics more affordably produced and available to patients around the world."
In August 2017, WuXi Biologics' cGMP facility in Wuxi city became the first China-based manufacturing facility to complete a U.S. Food and Drug Administration (U.S. FDA) Pre-License Inspection (PLI) for any biologics drug under FDA review, which paved the way for biologics commercial manufacturing.
AVB-S6-500 is a novel biologic drug candidate that neutralizes GAS6 with high affinity and is designed to inhibit the GAS6-AXL signaling pathway. Research has shown GAS6-AXL signaling to be a key molecular pathway that is believed to promote tumor growth and metastasis, as well as tumor immune evasion and resistance to other anticancer agents. In preclinical studies, AXL-GAS6 inhibition has shown both single agent activity and synergies with a variety of anticancer therapies including radiation therapy, immuno-oncology agents, and drugs that affect DNA replication and repair. Aravive expects to initiate a Phase I clinical trial of AVB-S6-500 in the first quarter of 2018.
About Aravive Biologics
Aravive Biologics is a privately held biopharmaceutical company developing novel, highly selective therapies designed to treat serious cancers and certain fibrotic diseases. The company's lead program is focused on the GAS6-AXL pathway. Aravive Biologics has generated strong preclinical data for its lead drug candidate in a variety of cancer models. The company is based in Houston, Texas, and receives support from the Cancer Prevention & Research Institute of Texas(CPRIT). For more information, please visit our website at www.aravive.com.
SOURCE WuXi Biologics
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.